The Dutch gene therapy company Uniqure will reduce its workforce by 20 percent, corresponding to 114 jobs. It is reported by Reuters. The company will also reduce its investments in R&D, research and development by more than half, in order to lower its costs.
Research manager Ricardo Dolmetsch will leave the company as part of the restructuring. Uniqure expects to generate cost savings of $180 million with full impact in three years.
The company has cash on hand of $628.6 million at the end of the year, which will finance operations until the second quarter of 2027.